Researchers have uncovered changes in the cellular response throughout lung damage caused by SARS-CoV-2—the virus behind ...

Using a newly developed mouse model, researchers found that exposure to the SARS-CoV-2 spike protein alone was enough to induce COVID-19-like symptoms including severe inflammation in the lungs.

Researchers at Umeå University have discovered that the SARS-CoV-2 variant omicron has developed a stronger binding to human lung cells through optimized interaction with heparan sulfate, a sugar ...

People with certain conditions, such as diabetes, renal failure, chronic lung disease, and immunocompromised persons, as well as the elderly, are considered to be at high risk of severe disease from ...

WEHI scientists discovered a drug that blocks long COVID in mice and may improve acute treatment options beyond current antivirals like Paxlovid. WEHI researchers have developed a drug compound that ...

the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells in the lungs remain elusive. Here we conducted integrated single-cell profiling of SARS-CoV-2 ...

Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

A SARS-CoV-2 particle enters a person's nose or mouth and floats in the airway until it brushes against a lung cell that has an ACE2 receptor on the surface. The virus binds to that cell ...

Tucked away on Mount Desert Island off the coast of Maine, the Jackson Laboratory (JAX) may seem removed from the pandemic ...

Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical ...

Now, SARS-CoV-2 circulates along with other common ... People over 65 Those with a weakened immune system Those with heart or lung diseases RSV doesn't usually come with long-term symptoms.